Similar results were reported by a multi-center randomized study of children with JIA-related uveitis refractory to MTX, showing that adding ADA (at a dose of 20–40 mg every two weeks) was significantly associated with fewer treatment failures compared to placebo (27% vs. 60%, p < 0.0001) [19]. The gene discussed is ADA; the disease is juvenile idiopathic arthritis.